Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.26), $0.07 worse than the analyst estimate of ($0.19).

Financial Outlook

Based on current operating plans, the Company expects that its existing cash, cash equivalents and marketable securities will fund its research and development programs and other operations through the first quarter of 2017.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance